USP28 and TP53BP1 are also significantly enriched in genome-wide screenings for resistance to anti-cancer drugs (in 6 or 9 out of the 10 anticancer drug screens, for TP53BP1 or USP28, respectively (Segal et al. 2023)). This evidence concerns the gene USP28 and cancer.